D.E. Shaw & Co
SLNO

D.E. Shaw & Co’s Soleno Therapeutics SLNO Stock Holding History

D.E. Shaw & Co’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,900
Closed -$2.64M – 4687
2025
Q1 		$2.64M Buy
+36,900
New +$1.8M ﹤0.01% 2405

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

D.E. Shaw & Co's SLNO Position: Q1 2026 in Review

D.E. Shaw & Co increased its Soleno Therapeutics (SLNO) stake by 424% in Q1 2026, buying an estimated $960K and bringing the position to 30,247 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3433.

D.E. Shaw & Co first reported a position in SLNO in Q1 2025 and has held it in 5 quarters since. The position peaked at $9.61M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • D.E. Shaw & Co held 30,247 shares of Soleno Therapeutics worth $1.01M as of Q1 2026.
  • D.E. Shaw & Co bought 24,480 Soleno Therapeutics shares in Q1 2026, an estimated $960K.
  • Soleno Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3433 holding.
  • D.E. Shaw & Co first reported a position in Soleno Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • D.E. Shaw & Co's Soleno Therapeutics position peaked at $9.61M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.